-
Subject Areas on Research
-
A combined treatment approach to anxiety in the medically ill.
-
A comparison of the efficacy of stimulus control for medicated and nonmedicated insomniacs.
-
A phase 1 trial of SGN-CD70A in patients with CD70-positive, metastatic renal cell carcinoma.
-
A phase 1 trial of vadastuximab talirine as monotherapy in patients with CD33-positive acute myeloid leukemia.
-
A phase 1 trial of vadastuximab talirine combined with hypomethylating agents in patients with CD33-positive AML.
-
A phase I trial of olanzapine (Zyprexa) for the prevention of delayed emesis in cancer patients: a Hoosier Oncology Group study.
-
A randomized trial examining the effectiveness of switching from olanzapine, quetiapine, or risperidone to aripiprazole to reduce metabolic risk: comparison of antipsychotics for metabolic problems (CAMP).
-
A selective imidazobenzodiazepine antagonist of ethanol in the rat.
-
Adinazolam sustained-release treatment of panic disorder: a double-blind study.
-
Adjunctive use of olanzapine in mood disorders: five case reports.
-
Alprazolam for endogenous depression.
-
Alprazolam in bipolar-I depressions.
-
Alprazolam reduces stress hyperglycemia in ob/ob mice.
-
Alprazolam vs amitriptyline in depressions with reduced REM latencies.
-
Alprazolam-induced manic reaction.
-
An empirical evaluation of the Arizona sexual experience scale and a simple one-item screening test for assessing antipsychotic-related sexual dysfunction in outpatients with schizophrenia and schizoaffective disorder.
-
Annals of Emergency Medicine Journal Club. Are 2 drugs better than 1 for acute agitation? A discussion on black box warnings, waiver of informed consent, and the ethics of enrolling impaired subjects in clinical trials: Answers to the January 2013 Journal Club questions.
-
Antipsychotic drug effects on brain morphology in first-episode psychosis.
-
Are Patients Taking Benzodiazepines at Increased Risk for Complications Following Primary Total Knee Arthroplasty?
-
Armodafinil as adjunctive therapy in adults with cognitive deficits associated with schizophrenia: a 4-week, double-blind, placebo-controlled study.
-
Association of Time to Treatment With Short-term Outcomes for Pediatric Patients With Refractory Convulsive Status Epilepticus.
-
Association of guideline publication and delays to treatment in pediatric status epilepticus.
-
Associations between Benzodiazepine Use and Neuropsychological Test Scores in Older Adults.
-
Atypical antipsychotic drugs and diabetes mellitus in a large outpatient population: a retrospective cohort study.
-
Atypical antipsychotic drugs and hyperglycemia in adolescents.
-
Atypical antipsychotics and pituitary tumors: a pharmacovigilance study.
-
Atypical antipsychotics rapidly and inappropriately switch peripheral fuel utilization to lipids, impairing metabolic flexibility in rodents.
-
Benzodiazepine administration patterns before escalation to second-line medications in pediatric refractory convulsive status epilepticus.
-
Benzodiazepine and beta-adrenergic receptor ligands independently stimulate phospholipid methylation.
-
Benzodiazepine anti-anxiety agents: prevalence and correlates of use in a southern community.
-
Benzodiazepine use and cognitive function among community-dwelling elderly.
-
Benzodiazepine use and risk of recurrence in bipolar disorder: a STEP-BD report.
-
Benzodiazepines as antidepressants: does GABA play a role in depression?
-
Benzodiazepines protect hippocampal neurons from degeneration after transient cerebral ischemia: an ultrastructural study.
-
Brain stem as a target site for the metabolic side effects of olanzapine.
-
Buspirone, chlordiazepoxide and diazepam effects in a zebrafish model of anxiety.
-
COMT158 polymorphism and hostility.
-
Case report: possible neuroleptic malignant syndrome associated with olanzapine.
-
Changes in glucose and cholesterol levels in patients with schizophrenia treated with typical or atypical antipsychotics.
-
Changes in weight and weight-related quality of life in a multicentre, randomized trial of aripiprazole versus standard of care.
-
Cholecystokinin excites interneurons in rat basolateral amygdala.
-
Clinical outcome in a randomized 1-year trial of clozapine versus treatment as usual for patients with treatment-resistant illness and a history of mania.
-
Clozapine markedly elevates pregnenolone in rat hippocampus, cerebral cortex, and serum: candidate mechanism for superior efficacy?
-
Clozapine treatment for suicidality in schizophrenia: International Suicide Prevention Trial (InterSePT).
-
Cognitive effects of atypical antipsychotic medications in patients with Alzheimer's disease: outcomes from CATIE-AD.
-
Comment on Nasrallah et al: lower mortality in geriatric patients receiving risperidone and olanzapine versus haloperidol.
-
Comparative effect of atypical and conventional antipsychotic drugs on neurocognition in first-episode psychosis: a randomized, double-blind trial of olanzapine versus low doses of haloperidol.
-
Comparative efficacy and safety of atypical and conventional antipsychotic drugs in first-episode psychosis: a randomized, double-blind trial of olanzapine versus haloperidol.
-
Comparison of enteral ethanol and benzodiazepines for alcohol withdrawal in neurocritical care patients.
-
Comparison of the effects of diphenylbarbituric acid, phenobarbital, pentobarbital and secobarbital on GABA-mediated inhibition and benzodiazepine binding.
-
Concurrent Opioid and Benzodiazepine Prescriptions Among Older Women Diagnosed With Breast Cancer.
-
Concurrent prescribing of opioids with other sedating medications after cancer diagnosis: a population-level analysis.
-
Consensus statement on depression, anxiety, and functional gastrointestinal disorders.
-
Consensus statement on panic disorder from the International Consensus Group on Depression and Anxiety.
-
Continuation treatment of panic disorder with high-potency benzodiazepines.
-
Course and predictors of weight gain in people with first-episode psychosis treated with olanzapine or haloperidol.
-
Crystal structures of the anticancer clinical candidates R115777 (Tipifarnib) and BMS-214662 complexed with protein farnesyltransferase suggest a mechanism of FTI selectivity.
-
Defining an appropriate management strategy for social anxiety disorder.
-
Design of the blockade of the glycoprotein IIb/IIIa receptor to avoid vascular occlusion (BRAVO) trial.
-
Determinants of seizure threshold in ECT: benzodiazepine use, anesthetic dosage, and other factors.
-
Development of new pharmacological agents for epilepsy: lessons from the kindling model.
-
Do benzodiazepines have a role in the prevention or treatment of coronary heart disease and other major medical disorders?
-
Does switching to a new antipsychotic improve outcomes? Data from the CATIE Trial.
-
Dopamine D2 receptor occupancy and cognition in schizophrenia: analysis of the CATIE data.
-
Dose-finding, safety, and tolerability study of an oral platelet glycoprotein IIb/IIIa inhibitor, lotrafiban, in patients with coronary or cerebral atherosclerotic disease.
-
Dosing recommendations and prescribing patterns for depressed medically ill hospitalized older patients.
-
Drug Trials in Status Epilepticus: Current Evidence and Future Concepts.
-
Early response to antipsychotic therapy as a clinical marker of subsequent response in the treatment of patients with first-episode psychosis.
-
Effectiveness of Quetiapine as a Sedative Adjunct in Mechanically Ventilated Adults Without Delirium.
-
Effectiveness of antipsychotic drugs in patients with chronic schizophrenia.
-
Effectiveness of clozapine versus olanzapine, quetiapine, and risperidone in patients with chronic schizophrenia who did not respond to prior atypical antipsychotic treatment.
-
Effectiveness of lurasidone in patients with schizophrenia or schizoaffective disorder switched from other antipsychotics: a randomized, 6-week, open-label study.
-
Effectiveness of olanzapine, quetiapine, and risperidone in patients with chronic schizophrenia after discontinuing perphenazine: a CATIE study.
-
Effectiveness of olanzapine, quetiapine, risperidone, and ziprasidone in patients with chronic schizophrenia following discontinuation of a previous atypical antipsychotic.
-
Effects of antipsychotic medications on psychosocial functioning in patients with chronic schizophrenia: findings from the NIMH CATIE study.
-
Effects of atypical antipsychotics on the syndromal profile in treatment-resistant schizophrenia.
-
Effects of clozapine, olanzapine, risperidone, and haloperidol on hostility among patients with schizophrenia.
-
Effects of olanzapine, quetiapine, and risperidone on neurocognitive function in early psychosis: a randomized, double-blind 52-week comparison.
-
Effects of switching from olanzapine, quetiapine, and risperidone to aripiprazole on 10-year coronary heart disease risk and metabolic syndrome status: results from a randomized controlled trial.
-
Efficacy and tolerability of olanzapine, quetiapine, and risperidone in the treatment of early psychosis: a randomized, double-blind 52-week comparison.
-
Efficacy of olanzapine in social anxiety disorder: a pilot study.
-
Endotracheal flumazenil: a new route of administration for benzodiazepine antagonism.
-
Establishing the neurobiologic basis of treatment in children and adolescents with generalized anxiety disorder.
-
Estimating suicidality as an outcome measure in clinical trials of suicide in schizophrenia.
-
Evacetrapib and Cardiovascular Outcomes in High-Risk Vascular Disease.
-
Evaluating short- and long-term impacts of a Medicaid "lock-in" program on opioid and benzodiazepine prescriptions dispensed to beneficiaries.
-
Factors associated with treatment delays in pediatric refractory convulsive status epilepticus.
-
First-line medication dosing in pediatric refractory status epilepticus.
-
Fixed-dose gabapentin augmentation in the treatment of alcohol withdrawal syndrome: a retrospective, open-label study.
-
Gabapentin Use in the Neonatal Intensive Care Unit.
-
Gaps and opportunities in refractory status epilepticus research in children: a multi-center approach by the Pediatric Status Epilepticus Research Group (pSERG).
-
Guidelines for sedation and anesthesia in GI endoscopy.
-
High-frequency organization and synchrony of activity in the purkinje cell layer of the cerebellum.
-
Impact of a palliative care program on end-of-life care in a neonatal intensive care unit.
-
Impact of antipsychotic treatment on nonfasting triglycerides in the CATIE Schizophrenia Trial phase 1.
-
Impact of olanzapine or risperidone treatment on insulin sensitivity in schizophrenia or schizoaffective disorder.
-
Impact of restarting home neuropsychiatric medications on sedation outcomes in medical intensive care unit patients.
-
Impact of symptoms of generalized anxiety disorder on the course of late-life depression.
-
Implications of atypical antipsychotic prescribing in the intensive care unit.
-
Improved analgesia, sedation, and delirium protocol associated with decreased duration of delirium and mechanical ventilation.
-
Indiplon is a high-affinity positive allosteric modulator with selectivity for alpha1 subunit-containing GABAA receptors.
-
Insight in first-episode psychosis.
-
International advances in the treatment of social phobia.
-
Intravenous ganaxolone for the treatment of refractory status epilepticus: Results from an open-label, dose-finding, phase 2 trial.
-
Involvement of AMPA receptors in the antidepressant-like effects of lithium in the mouse tail suspension test and forced swim test.
-
Long-term neurocognitive effects of olanzapine or low-dose haloperidol in first-episode psychosis.
-
Long-term neuroprotection by benzodiazepine full versus partial agonists after transient cerebral ischemia in the gerbil [corrected].
-
Management of cocaine-associated chest pain and myocardial infarction: a scientific statement from the American Heart Association Acute Cardiac Care Committee of the Council on Clinical Cardiology.
-
Metabolic effects associated with atypical antipsychotic treatment in the developmentally disabled.
-
Mitochondrial benzodiazepine receptors regulate steroid biosynthesis.
-
Motor cortex excitability after vagus nerve stimulation in major depression.
-
NMR studies of an immunomodulatory benzodiazepine binding to its molecular target on the mitochondrial F(1)F(0)-ATPase.
-
Neurocognitive effects of antipsychotic medications in patients with chronic schizophrenia in the CATIE Trial.
-
Neuropsychological course in the prodrome and first episode of psychosis: findings from the PRIME North America Double Blind Treatment Study.
-
New Developments in Insomnia Medications of Relevance to Mental Health Disorders.
-
Olanzapine and clozapine increase the GABAergic neuroactive steroid allopregnanolone in rodents.
-
Olanzapine and fluoxetine administration and coadministration increase rat hippocampal pregnenolone, allopregnanolone and peripheral deoxycorticosterone: implications for therapeutic actions.
-
Olanzapine and haloperidol in first episode psychosis: two-year data.
-
Olanzapine in PDD.
-
Olanzapine in refractory schizophrenia after failure of typical or atypical antipsychotic treatment: an open-label switch study.
-
Olanzapine in the treatment of post-traumatic stress disorder: a pilot study.
-
Olanzapine increases allopregnanolone in the rat cerebral cortex.
-
Olanzapine interactions with nicotine and mecamylamine in rats: effects on memory function.
-
Olanzapine on trial.
-
Olanzapine, new-onset diabetes mellitus, and risk for insulin overdose.
-
Olanzapine-associated diabetes mellitus.
-
Olanzapine-associated severe hyperglycemia, ketonuria, and acidosis: case report and review of literature.
-
One-year double-blind study of the neurocognitive efficacy of olanzapine, risperidone, and haloperidol in schizophrenia.
-
Opioid Prescribing After Nonfatal Overdose and Association With Repeated Overdose: A Cohort Study.
-
Opioid and benzodiazepine use during therapeutic hypothermia in encephalopathic neonates.
-
Panic disorder and social phobia: current treatments and new strategies.
-
Panic disorder: making clinical sense of the latest research.
-
Paroxetine in the treatment of generalised anxiety disorder.
-
Pharmacotherapy in stroke rehabilitation.
-
Pharmacotherapy of generalized anxiety disorder.
-
Pharmacotherapy of social anxiety disorder.
-
Predicting suicidal risk in schizophrenic and schizoaffective patients in a prospective two-year trial.
-
Predictors of antipsychotic medication adherence in patients recovering from a first psychotic episode.
-
Predictors of antipsychotic treatment response in patients with first-episode schizophrenia, schizoaffective and schizophreniform disorders.
-
Predictors of treatment discontinuation and medication nonadherence in patients recovering from a first episode of schizophrenia, schizophreniform disorder, or schizoaffective disorder: a randomized, double-blind, flexible-dose, multicenter study.
-
Prolactin levels in schizophrenia and schizoaffective disorder patients treated with clozapine, olanzapine, risperidone, or haloperidol.
-
Prostate cancer-associated SPOP mutations confer resistance to BET inhibitors through stabilization of BRD4.
-
Psychopharmacologic treatment of children and adolescents with anxiety disorders.
-
Quality of life during treatment with haloperidol or olanzapine in the year following a first psychotic episode.
-
Radiation inactivation studies of the benzodiazepine/gamma-aminobutyric acid/chloride ionophore receptor complex.
-
Randomized Trial of the Effect of Four Second-Generation Antipsychotics and One First-Generation Antipsychotic on Cigarette Smoking, Alcohol, and Drug Use in Chronic Schizophrenia.
-
Randomized, double-blind, placebo-controlled, international trial of the oral IIb/IIIa antagonist lotrafiban in coronary and cerebrovascular disease.
-
Reducing violence risk in persons with schizophrenia: olanzapine versus risperidone.
-
Relationship of past depressive episodes to symptom severity and treatment response in panic disorder with agoraphobia.
-
Relationships among neurocognition, symptoms and functioning in patients with schizophrenia: a path-analytic approach for associations at baseline and following 24 weeks of antipsychotic drug therapy.
-
Relaxation to assist sleep medication withdrawal.
-
Repeated seizures induce long-term increase in hippocampal benzodiazepine receptors.
-
Response to Strassels and Durham.
-
Restricting Benzodiazepines to Short-Term Prescription.
-
Results of phase 3 of the CATIE schizophrenia trial.
-
Risk Factors and Outcomes of Opioid Users with and Without Concurrent Benzodiazepine Use in the North Carolina Medicaid Population.
-
Risk Model-Guided Antiemetic Prophylaxis vs Physician's Choice in Patients Receiving Chemotherapy for Early-Stage Breast Cancer: A Randomized Clinical Trial.
-
Safety and Efficacy of Remimazolam Compared With Placebo and Midazolam for Moderate Sedation During Bronchoscopy.
-
Safety and antipsychotic efficacy of "forced" intramuscular olanzapine over five days: a case report.
-
Second-Generation Antipsychotics in Management of Acute Pediatric Bipolar Depression: A Systematic Review and Meta-analysis.
-
Sedation of children for emergency imaging.
-
Sexual dysfunction associated with second-generation antipsychotics in outpatients with schizophrenia or schizoaffective disorder: an empirical evaluation of olanzapine, risperidone, and quetiapine.
-
Simultaneous Benzodiazepine and SSRI Initiation in Young People With Anxiety Disorders.
-
Social phobia: biological aspects and pharmacotherapy.
-
Social phobia: issues in assessment and management.
-
Spousal depression, anxiety, and suicide after myocardial infarction.
-
Stiripentol in Dravet syndrome: results of a retrospective U.S. study.
-
Subsyndromal and syndromal depressive symptoms among older adults with schizophrenia spectrum disorder: Prevalence and associated factors in a multicenter study.
-
Texas Medication Algorithm Project: development and feasibility testing of a treatment algorithm for patients with bipolar disorder.
-
The association between benzodiazepine use and greater risk of neurocognitive impairment is moderated by medical burden in people with HIV.
-
The association of anticonvulsant use with fractures in spinal cord injury.
-
The association of psychotropic medication use with the cognitive, functional, and neuropsychiatric trajectory of Alzheimer's disease.
-
The effectiveness of antipsychotic medications in patients who use or avoid illicit substances: results from the CATIE study.
-
The efficacy of olanzapine for decreasing cue-elicited craving in individuals with schizophrenia and cocaine dependence: a preliminary report.
-
The international suicide prevention trial (interSePT): rationale and design of a trial comparing the relative ability of clozapine and olanzapine to reduce suicidal behavior in schizophrenia and schizoaffective patients.
-
The pharmacologic management of insomnia in patients with HIV.
-
Time from convulsive status epilepticus onset to anticonvulsant administration in children.
-
Time to Treatment in Pediatric Convulsive Refractory Status Epilepticus: The Weekend Effect.
-
Time to discontinuation of atypical versus typical antipsychotics in the naturalistic treatment of schizophrenia.
-
Time-lapse mapping of cortical changes in schizophrenia with different treatments.
-
Treatment of social phobia with benzodiazepines.
-
Treatment outcomes of patients with tardive dyskinesia and chronic schizophrenia.
-
Understanding the sleep-wake cycle: sleep, insomnia, and the orexin system.
-
Use of antidepressants by nonpsychiatrists in the treatment of medically ill hospitalized depressed elderly patients.
-
Use of benzodiazepines in panic disorder.
-
What CATIE found: results from the schizophrenia trial.
-
Zonisamide prevents olanzapine-associated hyperphagia, weight gain, and elevated blood glucose in rats.
-
[3H]-flunitrazepam-labeled benzodiazepine binding sites in the hippocampal formation in autism: a multiple concentration autoradiographic study.
-
[Benzodiazepine receptors of the mouse glioblastoma cell line: the anomalous effect of gamma-aminobutyric acid on diazepam binding].
-
[Benzodiazepines consumption and risk of dependence in institutionalized geriatric patients].
-
[Molecular mechanisms of the pharmacologic action of benzodiazepines].
-
gamma-Aminobutyric acid(A) neurotransmission and cerebral ischemia.
-
Keywords of People